Young at heart : pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells by A. Gowran et al.
Review Article
Young at Heart: Pioneering Approaches to Model Nonischaemic
Cardiomyopathy with Induced Pluripotent Stem Cells
Aoife Gowran,1 Marco Rasponi,2 Roberta Visone,2 Patrizia Nigro,1 Gianluca L. Perrucci,3
Stefano Righetti,4 Marco Zanobini,5 and Giulio Pompilio1,3,5
1Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, Via Parea 4, 20138 Milan, Italy
2Department of Electronics, Information and Bioengineering, Politecnico di Milano, Piazza Leonardo da Vinci 32,
Building No. 21, 20133 Milan, Italy
3Department of Clinical Sciences and Community Health, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy
4Cardiology Unit, San Gerardo Hospital, Via Giambattista Pergolesi 33, 20052 Monza, Italy
5Department of Cardiac Surgery, Centro Cardiologico Monzino-IRCCS, Via Parea 4, 20138 Milan, Italy
Correspondence should be addressed to Aoife Gowran; agowran@ccfm.it
Received 27 November 2015; Accepted 9 February 2016
Academic Editor: Gary E. Lyons
Copyright © 2016 Aoife Gowran et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A mere 9 years have passed since the revolutionary report describing the derivation of induced pluripotent stem cells from human
fibroblasts and the first in-patient translational use of cells obtained from these stem cells has already been achieved. From the
perspectives of clinicians and researchers alike, the promise of induced pluripotent stem cells is alluring if somewhat beguiling. It
is now evident that this technology is nascent and many areas for refinement have been identified and need to be considered before
induced pluripotent stem cells can be routinely used to stratify, treat and cure patients, and to faithfully model diseases for drug
screening purposes. This review specifically addresses the pioneering approaches to improve induced pluripotent stem cell based
models of nonischaemic cardiomyopathy.
1. Introduction
The American Heart Association’s Scientific Statement from
the Council of Clinical Cardiology defines cardiomyopathy
as “a heterogeneous group of diseases of the myocardium asso-
ciated with mechanical and/or electrical dysfunction, which
usually (but not invariably) exhibit inappropriate ventricular
hypertrophy or dilatation, due to a variety of etiologies that
frequently are genetic” [1]. Predominately, cardiac diseases
involving the myocardium are caused by atherosclerosis
and termed ischaemic cardiomyopathies. However, there is
a plethora of diseases linked to the myocardium which
are unconnected with atherosclerosis and not ischaemic in
nature. Nonischaemic cardiomyopathies (NICM) are clas-
sified as primary and secondary, where the pathology in
the former is confined to the heart whilst for the latter the
cardiomyopathy is due to underlying systemic disease. The
prevalence of NICM in patients enrolled in heart failure
trials ranged from 19% to 53%; however, there may be
significant bias in this data as other reports show much
lower levels in unselected patient populations with greater
gender balance [2]. The diagnosis of the specific NICM is
not straightforward requiring careful clinical correlation,
cardiac magnetic resonance imaging, and frequently myo-
cardial biopsy [3]. Despite many NICM being genetic in
origin, the exact underlying causes and pathological molec-
ular mechanisms of NICM are not well characterised
in comparison to ischaemic cardiomyopathy and many
remain unknown [2]. Pathological tissue characteristics
of the myocardium in NICM are inflammatory oedema,
abnormal calcium handling, fatty infiltration, fibrosis, and
the formation of scar tissue which has been shown to be
the genesis of life threatening cardiac arrhythmia [1–3].
The causative factors associated with heart failure in NICM
are numerous and heterogeneous in nature such as genetic
mutations [1], excessive alcohol consumption, malnutrition,
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cytotoxic drugs, exposure to infectious agents, autoimmu-
nity, and hyperthyroidism [2]. Logically the removal of
the causative factor in NICM affects the clinical course
of the heart failure; however, the causative factor is often
difficult to eliminate or control, or is not known. Mortal-
ity rates (2-year follow-up) have been found to be better
in NICM (48%; idiopathic dilated cardiomyopathy) com-
pared to ischaemic cardiomyopathy (69%; coronary heart
disease) [4]. Another study showed (5-year follow-up)
that the survival rate was higher for NICM (69%) com-
pared to ischaemic cardiomyopathy (59%) [5]. Responses of
NICM patients to essential cardiac drugs (e.g., angiotensin-
converting enzyme inhibitors, beta-blockers, and diuretics)
do not differ to that of patients with ischaemic cardiomy-
opathy [6]. However, 2 trials (Prospective Randomised Study
of Ventricular Function and Efficacy of Digoxin, PROVED
[7], and Randomised Assessment of Digoxin and Inhibitors
of Angiotensin-Converting Enzyme, RADIANCE [8]) have
shown positive differences (compared to ischaemic heart
disease patients) in left ventricle ejection fractions in patients
with nonischaemic dilated cardiomyopathy (DCM) receiv-
ing digoxin alone or in combination with inhibitors of
angiotensin-converting enzyme. Furthermore, other drugs
such as pentoxifylline (an inhibitor of tumor necrosis factor-
alpha), growth hormone, and amiodarone (a class III antiar-
rhythmic agent) were found to elicit better responses in
NICM patients [6].
In spite of this, treatment efficacy becomes limited for
NICM patients with gravely decreased cardiac functions
which can only be resolved by heart transplant. Alternatively,
cardiac stem cell therapy is a developing approach which
is currently undergoing clinical trials to assess the ability
of various stem cells to functionally rejuvenate the heart
[9, 10]. Numerous appraisals of stem cell transplantation
for cardiac diseases have concluded that although safe, cell
transplantation does not promote significant gains in cardiac
functions and therefore further investigations are needed in
forthcoming trials [11–13]. Thus, enhancing cardiac cell ther-
apy for myocardial regeneration requires the development of
pioneering approaches stemming from multiple disciplines:
biology, engineering, and clinical medicine.
Pluripotent stem cells (PSCs) derived from early embryos
(embryonic stem cells (ESCs) [14]) or induced following
the reprogramming of somatic cells (induced pluripotent
stem cells (iPSCs) [15]) represent a groundbreaking advance
in regenerative medicine. Whilst both types of PSCs are
indistinguishable in terms of pluripotency, iPSCs have a
distinct advantage over ESCs as they can be autologously
generated and are not connected to major ethical concerns.
Cells derived from both ESCs and more recently iPSCs have
been used in clinical trials tackling tissue regeneration and
as drug screening tools. Furthermore, iPSCs can be derived
from individuals with a genetic disease (or carriers) and
thus are an important unlimited cell source which can be
differentiated into specific cell types, including cardiomy-
ocytes (iPSC-CMs) that display the relevant pathophysiology.
However, continued innovations are needed to maximise the
proposed power of stem cell derived cardiomyocytes as cell
products and laboratory tools.
Significant advances in generating stem cell derived
human cardiomyocytes and bioengineering strategies offer an
unprecedented opportunity to create bioengineered systems
for the more accurate simulation of the native environment.
Considerable progress has been made on the use of static
2D cultured human stem cell derived CMs [16–20]. However,
the predictability of such systems is still limited. Microtech-
nologies have been increasingly adopted to study PSCs and
progeny cells in vitro, particularly to build 3D culture systems,
which are beginning to replace existing traditional platforms.
The rapid fabrication of polydimethylsiloxane- (PDMS-)
based biocompatible microfluidic devices, especially suitable
in bioengineering, was made possible by the widespread use
of soft lithography techniques developed during the 1990s by
the Whitesides group [21]. Besides the intrinsic advantages
of miniaturisation, such as the reduction of reagents and
cell numbers required for each experiment, microdevices
allow for the accurate generation of 3D tissues and a high
control over the cell microenvironment providing well-
defined chemical, geometrical, mechanical, or electrical cues
[22, 23]. Moreover, the integration of microelectrodes allows
the stimulation of heart cells in parallel with monitoring
their contraction. Particular effort has been recently spent
on the development of heart-on-chip platforms by taking
advantage of microfabrication, biomaterials, and iPSCs [24,
25]. These systems represent in vitro models capable of
imitating the natural heart muscle and promise to increase
the predictability of drug screening and disease modelling at
unprecedented levels.
2. Induced Pluripotency
The discovery of iPSC technology has revolutionised stem
cell based research and personalised medicine. This technol-
ogy permits the reprogramming of terminally differentiated
somatic cells and reprogram them into intermediary iPSCs
by the ectopic expression of pluripotency factors (octamer-
binding transcription factor 4 (OCT4) and SRY- (sex deter-
mining region Y-) box 2 (SOX2), kruppel-like factor 4 (Klf4),
and V-Myc avian myelocytomatosis viral oncogene homolog
(c-Myc); OSKM) [26]; the later addition of Nanog and Lin28
enhanced efficiency [27]). Upon overexpression of these
factors, somatic cells are capable of activating endogenous
core-pluripotency pathways which modulate the expression
of genes regulating cell fate [28]. The ensuing iPSCs can be
differentiated into functional cells of interest, for example,
neurons [29], cardiomyocytes [30], vascular cells [31, 32],
chondrocytes [33], pancreatic cells [34], and hepatocytes [35],
amongst other cell types resident in organs originating from
all 3 germ layers. Since the initial report of the iPSC platform,
there have been a series of methodological evolutions which
have greatly increased the efficiency of the process and the
appeal for translational use.
Induced pluripotency has been shown to be a universally
applicable method [36] as iPSCs have been derived from a
number of founder cells other than skin fibroblasts, such
as renal epithelial cells [37], endometrial stromal cells [38],
mesenchymal stem cells [39], differentiated T-cells [40], and
peripheral blood mononuclear cells (PBMCs) [41]. Despite
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the broad range of founder cells, some types, for instance,
PBMCs, are more applicable for the derivation of iPSCs
than others. Some reasons for this enhanced suitability
are the less invasive nature of sampling needed to obtain
the cells, the preexistence of “in-house” sample processing
logistics, the ease of in vitro expansion and purification steps,
the low exposure to environmental mutagens, and reduced
processing times.
The mode of delivering reprogramming factors and the
selection of reprogramming factors themselves have been
subject to major advances. The field has moved away from
retro- [15, 26] and lentiviral [27] mediated transfection to
using nonintegrating viral vector-based methods that pre-
serve high reprogramming efficiency rateswhilstmaintaining
genome integrity (e.g., Sendai virus) [42]. Furthermore,
Sendai virus transduced cells do not need further transgene
excision and the presence of virus in the cell cytosol can be
cleared by elevated temperatures or siRNA treatment. In spite
of this, the original retro- and lentiviral based systems are still
routinely utilised for basic research and disease modelling
purposes as there is less onus on translational potential.
Groups with a translational outlook favour nonintegrating
methods of reprogramming such as episomal vectors [41],
microRNAs [43], and protein transduction [44, 45]. These
clinically orientated approaches to reprogramming come at
the cost of reduced efficiency. However, when combined
with the original OSKM reprogramming factors, noninte-
grating pluripotency factors such asmiRNA, smallmolecules,
and epigenetic regulators have drastically increased repro-
gramming efficiency rates from 0.01% (OSKM) [36] to a
reported near 100% efficient method termed deterministic
reprogramming [46]. In an effort to decode and control the
molecular mechanisms of induced pluripotency, researchers
have suggested that there is a more nuanced and fluid
control of pluripotency [47, 48] which has been termed
the “seesaw model” entailing the balance between endoge-
nous/exogenous pluripotency and lineage-specifying factors
[49]. Indeed, investigations have shown that many of the
core-pluripotency factors OCT4 and SOX2 can be replaced
by lineage-specifying genes (e.g., GATA binding protein 3
(GATA3), zinc finger protein 521 (ZNF521), orthodenticle
homeobox 2 (OTX2), and paired box 6 (PAX6)) during
human iPSC generation [50]. Further studies, based on pre-
existing knowledge regarding the induction of pluripotency
in the absence of exogenous genes [51, 52], have demonstrated
that small molecules can replace all the core-pluripotency
genes (including OCT4) to induce the fully chemical-based
reprogramming of murine fibroblasts [53], albeit at very low
efficiency rates.
Lastly, protocols for culturing iPSCs with fully defined
xeno-free media and matrices have evolved in parallel to
advances in efficient reprogramming methods. Several com-
mercially available work flow products now permit the fully
defined isolation and culture of human iPSCs without the
need for specialist knowledge or equipment. These products
have vastly improved the efficiency and quality and certainly
have reduced the labor costs (in terms of work hours) associ-
ated with performing iPSC-based research. Remarkably, the
entire process of deriving, characterising, and differentiating
multiple iPSC lines in parallel has now been automated
in a modular, robotic high-throughput platform [54]. The
advances in streamlining, upscaling, and automation suggest
that iPSCs will soon become useful in large-scale efforts to
tackle complex diseases, stratify patient treatment responses,
and adopt personalised drug regimes. Furthermore, the cre-
ation of national human leukocyte antigen (HLA) haplotype-
matched iPSC biobanks large enough to cover entire popu-
lations may serve to cover medical situations where there is
an acute need for replacement cells, for example, stroke and
myocardial infarction [55–57].
From these richly diverse procedures to obtain iPSCs,
scientists and clinicians are free to tailor their choice of
methodological approach to generate iPSCs based on their
own priorities be it transduction efficiency, high reprogram-
ming fidelity, authentic disease modelling, or clinical use.
3. iPSC Differentiation and
Derivation of Cardiomyocytes
The most common destiny of iPSCs is to undergo directed
differentiation where the subsequent differentiated cells can
be used for a myriad of purposes such as disease models,
drug toxicity screens, novel drug discovery, tissue develop-
mental models, and cell-therapy products. Many of these
applications require large numbers of cells (in the order of
107 to 109 cells) generated in a chemically defined, xeno-free,
reproducible, scalable, and cost-effective manner [58, 59].
Current CM differentiation protocols, although now effi-
cient compared to early protocols (e.g., fetal bovine serum-
based embryoid body [30] or inductive coculture on visceral
endoderm-like (END-2) cells [60]), still lack the rigorous
derivation standards mentioned above: for example, many
still involvemedia containing animal-based components [61].
Most CM differentiation protocols rely on emulating embry-
onic mesoderm induction signals such as bone morpho-
genetic protein (BMP), Notch, and Wnt signalling [62], with
the following generation of heart-field-specific progenitors by
inhibiting Wnt, BMP, and TGF-beta signalling [58, 61]. CM
yields of 106–109 cells with high purity rates (80%) have been
reported, while higher purity (95–99%) levels are achievable
following metabolic selection by glucose deprivation [58, 61,
63]. From a translation point of view, metabolic CM selection
is preferable to genetic selection strategies [64] as the former
does not involve genetic modification. However, despite
high levels of CM purity more in-depth characterisations
of resulting CMs have revealed that there is a mixture of
CM subtypes (atrial-, ventricular-, and nodal-like CMs) in
the postdifferentiation cell population [30, 59]. This issue is
of paramount importance since there is growing demand
for CM subtype-specific cell-therapy products suitable for
myocardial repair. Interestingly, augmenting retinoic acid
signalling with a pan-retinoic acid receptor antagonist BMS-
189453 elevates the number of ventricular CMs (as assessed
by the presence of ventricular-specific markers IRX-4 and
MLC-2V, ventricular-like action potentials, and calcium han-
dling) [65], indicating that this signalling pathway could
be of use in controlling CM subtype specification. In order
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to more accurately reflect the cellular composition of the
myocardium, the complexity of iPSC-derived cardiac tissue
needs to be expanded, for example, including a wider range
of cardiovascular cells and more mature CMs [66].
Alternatively, direct cardiac reprogramming in vitrooffers
the potential to skip the intermediary iPSC stage in the pro-
duction of CMs for heart regeneration [67]. A number of
groups have demonstrated that induced CMs (iCMs) can
be generated from human fibroblasts reprogrammed with
cardiac-specific transcription factors (GATA binding protein
4 (GATA4), heart and neural crest derivatives expressed 2
(Hand2), T-box transcription factor 5 (T-box5), myocardin,
myocyte enhancer factor 2C (Mef2c), estrogen-related
receptor-beta (Esrrb), and mesoderm posterior basic helix-
loop-helix transcription factor 1 (Mesp1)), and muscle-
specific microRNAs (miR-1 and miR-133) [68–70]. However,
these approaches have not been without problems as repro-
gramming efficiencies are low (0.5–20%) and reproducibility
has been problematic [71, 72]. In contrast, the direct repro-
gramming of murine cardiac fibroblasts in vivo is more
efficient which raises the tempting possibility that the direct
delivery of cardiac reprogramming factors into the damaged
heart may be possible [36]. Nevertheless, the matters of
potential genomic damage caused by the random integration
of transcription factors by retroviral vectors, the risk of
arrhythmia, the presence of mixed CM subtypes with vary-
ing degrees of maturity, and the lack of translation into large
animal or human experiments remain major hurdles for
this emerging avenue of iPSC-based cardiac cell therapy.
Furthermore, the length of time that iCMs survive posttreat-
ment and indeed whether this approach is more suitable for
acute or chronic cardiac clinical-needs remain open ques-
tions. To overcome these challenges, a deeper understanding
of themechanisms governing cell reprogramming is essential
which will be aided by transcriptomic [73] and epigenomic
analyses [36].
4. Harnessing the Functional Maturity of
CMs Derived from iPSCs
One of the most pervasive obstacles in iPSC research and
development is the generation of mature iPSC-CMs and the
full recapitulation of disease. iPSC-CMs express high levels of
cardiac genes and display spontaneous beating (48.6 average
beats per minute), which upon electrophysiological analysis
can be allotted to predominantly ventricular-like (48–74%)
but also atrial- and nodal-like action potentials (APs) [30, 74–
77]. However, upon closer examination it has been shown
that iPSC-CMs do not exhibit many morphological and
functional characteristics of adult CMs. For instance, iPSC-
CMs are small in size with multiangular symmetries [78],
have unorganised sarcomeres and alteredCa2+ transients [79]
due to the lack of t-tubuli [80]. iPSC-CMs display altered APs
resulting from discrepancies in certain cardiac ion channels
[75, 81], namely, low inward rectifier potassium (Kir) and
high cardiac pacemaker “funny” (If ) channel densities [75].
Thus, iPSC-CMs are electrophysiologically immature and
have a depolarisedmembrane potential and slowAPupstroke
velocities (reviewed in [81]). Clearly these differences impact
the usefulness of iPSC-CMs as drug screening and disease
modelling tools [82] and represent a serious safety issue in
relation to the development of cell-therapy products. This
coupled to the increasing demand for novel cardiovascular
therapies and tailored patient treatment plans signifies that
improving iPSC-CMs is a clinical imperative [83].
Long term culture, electrical stimulation, and exposure
to mechanical forces are some of the pioneering strategies
to influence the maturity of iPSC-CMs in order to more
faithfully reprise the in vivo phenotype. Additionally, recre-
ating the in vivo tissue- and cytoarchitecture by culturing
iPSC-CMs in 3D scaffolds in the presence of other cardio-
vascular cell types can also influence the maturity of iPSC-
CMs so that they may become more attractive for future
use in multiple applications [82, 84]. It is conceivable that
the maturity of iPSC-CMs maybe tunable to offer the best
possible tool to yield relevant and useful information which
is balanced with the degree of complexity in the engineered
model. Reproducing a myocardial-like environment in vitro,
through biochemical (e.g., natural extracellular matrix-like
growth substrate, soluble factors), mechanical (e.g., cyclic
strain), and electrical stimulation, has been reported to be a
successful strategy to induce cell differentiation into mature
CMs [85]. Likewise, in order to generate a more functional
and physiological-like tissue, different strategies have been
exploited to guide cells to form 3D constructs by promoting
the spontaneous formation of the tissue without the use of
exogenous synthetic materials or driving the autoassembly of
cell laden hydrogels at specific anchoring points [24]. Cells
embedded in hydrogels (i.e., collagen I, fibrin, andMatrigel)
exhibited the ability to organise themselves around fixed
or mobile posts [86–88] or hydrogels could be inserted
into casting moulds to form circular strips circumferen-
tially aligned around cylindrical structures [89, 90]. Once
the 3D constructs are formed, the posts can be used as
passive components to evaluate cardiac contractile activity
by optically monitoring postdeflection in response to forces
generated by constructs [91] either spontaneously or under
the effect of electrical pacing. Furthermore, posts have also
been exploited as active components (i.e., springs) to control
tissue remodelling and stiffening. For example, modulating
the elastic modulus of posts or adhering nickel spheres
on the post tops so that their position can be controlled
throughmagnetic field imposition has been shown to control
tissue stiffening during tissue remodelling [92]. Moreover,
mechanical stimulation enhanced a physiological hypertro-
phy and architecture of cardiac constructs as demonstrated
by Tulloch and colleagues [93]. Specifically, the imposition
of uniaxial cyclic stress to iPSC-CMs embedded in a 3D
collagen matrix resulted in cardiac constructs showing fiber
alignment and myofibrillogenesis and sarcomeric banding
[93] and increased the duration of cellular action potentials.
Additionally, although mechanical stimulation was able to
guide the maturation of CM calcium handling machinery
[94], it was not able to achieve a CMmaturation stage similar
to that obtainedwith electrical stimulation [95]. Recent inves-
tigations based on exploiting the spontaneous engineered
heart tissue (EHT) formation techniques discussed above
have demonstrated that coupling mechanical and electrical
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stimulations supports a better functional maturity of cardiac
tissue. Indeed, Miklas et al. [96] obtained cardiac microtis-
sues exhibiting more relevant contraction amplitudes and
forces with a superior development of sarcomeric structures
by applying electromechanical stimulation (1ms biphasic 3-
4V/cm pulses at 1Hz; 5% constant stretch) to neonatal rat
CMs seeded in collagen gels. These results are in agreement
with Boudou and coworkers’ demonstration that the combi-
nation of electrical stimulation (1ms biphasic 6V/cm pulses
at 0.2Hz) and auxotonic load strongly improves both the
structure and function of cardiac microtissues [22]. Godier-
Furne´mont et al. [97] recently formed EHT strips using
a mixture of collagen I, Matrigel, and neonatal rat heart
cells, proving that electromechanical stimulation performed
at physiological frequencies supports EHT functional matu-
ration. Furthermore, precondensed EHT strips subjected to
dynamic mechanical stretch (supporting auxotonic contrac-
tion) in combination with electrical stimulation (3ms bipha-
sic 5V pulses at 4Hz) showed a positive force-frequency
relationship (FFR) and cells within the construct exhibited
mature sarcoplasmic calcium handling machinery [97].
CMs typically act in concert with fibroblasts, vascular
cells, and neurons, and these cell-cell interactions tightly
regulate heart development and function in vivo [98]. Cocul-
ture systems reproducing this cell heterogeneity have been
reported to enhance cardiac tissue performance and func-
tionality in vitro. Cardiac fibroblasts (CFs), in physiological
conditions, provide a scaffolding structure for CMs and coor-
dinate the pump function of the heart [99]. In vitro 3D cocul-
tures of CFs with CMs in physiological ratios (2 : 1) conferred
enhanced functionalities on engineered cardiac microtissues,
improving cellular elongation, alignment, viability, and cell-
cell interaction via connexin and cadherin proteins [100–102].
Sympathetic neurons regulate heart rate, excitation conduc-
tion velocity, and myocardial contraction/relaxation mecha-
nisms. Takeuchi et al. developed different systems [103–105]
employing multielectrode array substrates to compartmen-
tally coculture autonomic nervous system neurons with CMs
or iPSC-CMs, achieving the formation of functional synapsis
between the two cell populations. This method allowed the
control and modulation of the cardiac contraction rhythm in
a quasi-natural way, by electrically stimulating sympathetic
neurons [106]. In the native myocardium, there is a high den-
sity of capillaries for cardiac cells, with a proportion of about
three endothelial cells (ECs) per CM [107]. Integrating a
vascular network within in vitro cardiac constructs enhanced
CM survival and spatial reorganisation in a 3D configuration
[108] and can thus increase the physiological relevance of
generated tissues for fundamental biological studies or for
implantation in patients. In the last years, many devices have
been designed to guide perfusable microvascular network
formation in a highly organised way by shaping luminal
structures in the substrates to receive and arrange ECs.
Exploiting this technique, Vollert et al. [109] increased CM
density within contracting EHTs, generating small perfusable
tubular structures. The Radisic group engineered a cardiac
tissue around an organised capillary network grown between
a vein and an artery, which improved construct functional
properties, cell striation, and cell-cell junctions [110].
Table 1 lists a set of microdevices, together with the
particular stimulating features, developed to differentiate in
vitro stem cells toward the cardiac lineage.
5. Modelling NICM Using iPSCs
Since there is a low probability of obtaining cardiac muscle
biopsies and with the high risk involved in these procedures,
cardiovascular disease models using animals or animal-
derived tissues/cells are themajorways to identify pathophys-
iological mechanisms and screen for drug toxicity. However,
systematic reviews have shown that translating animal model
findings into a human setting is hampered by the failure
of animal models to fully recapitulate human disease [116,
117] further exacerbating the lack of new cardiovascular
drugs [83] and the high failure rates in drug development
due to cardiotoxicity [118, 119]. This emphasises the need
for alternative approaches. Hence, iPSC-CMs represent a
fruitful avenue to fill this gap and judging from the flurry
of publications involving iPSC-CMs, which followed the
initial description of iPSC technology, one would assume
that the application of iPSC-CMs to model cardiac diseases
has been extremely successful. To an extent this is true;
however, so far the cardiac diseases modelled using iPSC-
CMs are confined mostly to early onset monogenic diseases
and thus are relatively easy to model with iPSC-CMs which
resemble immature fetal CMs. A more daunting task is the
replication of adult onset cardiac diseases associated with
multiple genes, cardiac diseases with unknown pathological
mechanisms, or subclinical symptoms. Yet the move towards
this era is evident in the evolving literature on cardiac disease
modelling with evermore complex cardiac diseases being
demonstrated in iPSC-CMs. Indeed, several new insights
have been gleamed following the recapitulation of cardiac
diseases in patient specific CMs such as new disease mecha-
nisms and responses to potential novel therapeutics. Figure 1
illustrates the application of iPSCs in cardiovascular research.
Dilated cardiomyopathy (DCM), themost common form
of NICM (Table 2 lists NICMs modelled with patient iPSC-
CMs), is caused by mutations in cardiac troponin T (cTnT)
gene andwas successfully recapitulated in CMs induced from
patient specific iPSCs (DCM-CMs) by Sun et al. [120]. DCM-
CMs displayed abnormal punctate distribution of sarcomeric
𝛼-actinin and blockade of the beta-adrenergic pathway with
metoprolol enhanced myofilament organisation and con-
ferred resistance tomechanical damage. Furthermore, partial
functional improvement and increased [Ca2+]
𝑖
were observed
when sarcoplasmic/endoplasmic reticulum calcium ATPase
3 (Serca2a) was overexpressed in DCM-CMs. Another iPSC-
CM-modelled cardiac disease associated with mutations in
genes encoding sarcomeric proteins is hypertrophic car-
diomyopathy (HCM) which is responsible for arrhythmias
and sudden cardiac death [121]. HCM-CMs containingmuta-
tions in the myosin heavy chain 7 (MYH7) gene were
pathologically enlarged and had contractile arrhythmias
with dysregulated Ca2+ cycling and concentrations which
responded favourably to verapamil (a L-type Ca2+ channel
blocker). Additionally, HCM-CMs showed increased levels
of hypertrophic-related genes (GATA4, cTnT, MYH7, and
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Table 1: Cardiac differentiation in microdevices featuring high control over physicochemical stimulation.
Physics Stimulation type Cellenvironment Cell type Readout Reference
Biochemical Matrigel, B27 minus
insulin supplement 3D hiPSCs
Sarcomeric
𝛼-actin, and DAPI Mathur et al. (2015) [24]
Biomimicry
Nanofiber scaffolds
(macroscale) 3D
Embryoid
bodies (EBs)
from mESC
Sarcomeric
𝛼-actin, and
connexin 43
Ghasemi-Mobarakeha et al.
(2013) [111]
Collagen type I
interspersed with
laminin
3D EBs from mESC PECAM (FITC),beating cells Battista et al. (2005) [112]
Electrical
Electrodes – 304
stainless steel and
titanium rods (10 cm
× 1.3mm)
2D hESC Troponin T,beating cells Serena et al. (2009) [113]
Indium tin oxide
electrodes 2D hASC
Connexin 43,
F-actin, and
beating cells
Tandon et al. (2010) [114]
Carbon electrodes 3D mPSC Contraction forcemeasurement Boudou et al. (2012) [22]
Electrodes in a Petri
dish after biowire
maturation
3D hPSC
Sarcomeric
𝛼-actinin,
Troponin T, and
beating cells
Nunes et al. (2013) [95]
Mechanical Auxotonic load 3D mPSC, hiPSC Calcium release,beating cells Thavandiran et al. (2013) [23]
Electromechanical
PDMS/CNT
electrodes + cyclic
strain
2D hBM-MSC qRT-PCR Pavesi et al. (2015) [115]
Carbon electrodes,
static stretch 3D mPSC Beating cells Miklas et al. (2014) [96]
Graphite electrodes,
auxotonic contraction 3D mPSC
Calcium release,
beating cells
Godier-Furne´mont et al.
(2015) [97]
Coculture
Mouse endothelial
cells 3D
Neonatal mouse
CMs
TUNEL
(apoptosis),
beating cells, and
connexin 43
Narmoneva et al. (2004) [108]
Organised capillary
network between
artery and vein
2D Neonatal ratsCMs
Troponin T,
connexin 43, and
beating cells
Chiu et al. (2012) [110]
Superior cervical
ganglion neurons 3D iPSC-CMs Beating cells
Takeuchi et al. (2011, 2012, and
2013) [103–105], Miwa et al.
(2013) [106]
myosin light chain 2 (MYL2)) which was evident following
prolonged culture (40 days).
Arrhythmogenic right ventricular cardiomyopathy
(ARVC), also known as arrhythmogenic cardiomyopathy,
is a cardiac disease of genetic origin which occurs due to
mutations in cardiac desmosomal proteins, for example, pla-
kophilin-2 (PKP2), which leads to ventricular tachyarrhy-
thmias progressing to heart failure. ARVC has beenmodelled
with patient iPSC-CMs by several groups [122–124]. ARVC-
CMs displayed reduced PKP2, connexin-43 (Cx43), and
peroxisome proliferator-activated receptor- (PPAR-) gamma
expression, increased lipogenesis and enhanced adipogenic
differentiation potential, and other electrophysiological irreg-
ularities (e.g., prolonged field potential risetime). Intrigu-
ingly, a model system developed by the Chen group [124, 140]
showed that, in order to fully recapitulate meaningful ARVC
disease readouts, patient specific iPSC-CMs needed to be
metabolically matured and stimulated with activators of the
PPAR-gamma pathway which is hyperactivated in ARVC
right ventricles [125]. This approach highlights the need to
carefully consider the maturation state of iPSC-CMs and
the culture conditions before constructing disease readouts
Stem Cells International 7
Table 2: NICMs modelled with patient iPSC-CMs.
NICM Cultureenvironment CM disease readouts
∗ Selected interventions (effect)∗ Reference
Dilated
cardiomyopathy
Embryoid bodies
(EBs)
Disturbed sarcomeric organisation.
↑Sensitivity to positive inotropic
and biomechanical stress (cyclic
stretch). ↓Sarcoplasmic reticulum
(SR) Ca2+ storage and altered Ca2+
handling. ↓CM contraction forces.
Overexpression of Serca2a
(↑[Ca2+]
𝑖
transients and CM
contraction forces).
Beta-1-adrenergic blockade
(resistance to biomechanical
stress and improved myofilament
organisation)
Sun et al.
(2012) [120]
Hypertrophic
cardiomyopathy EBs
CM hypertrophy. Disturbed
sarcomeric organisation.
↑Multinucleation.
↑Hypertrophy-related genes.
Expression of atrial natriuretic
peptide. ↑Beta-/alpha-myosin ratio.
Calcineurin activation. NFATc4.
↑Myofibril content. ↑Membrane
capacitance. Presence of arrhythmic
waveforms. ↑Irregular beating
frequencies. CM hypercontractility.
Irregular Ca2+ transients. ↓SR Ca2+
release and ↑[Ca2+]
𝑖
Blockade of calcineurin-NFAT
interaction (40% reduction in
CM cell size). Beta-adrenergic
stimulation (↑irregular Ca2+
transients and arrhythmia).
Coadministration of
beta-adrenergic blocker +
beta-adrenergic agonist
(↓hypertrophy, Ca2+ handling
deficiencies, and arrhythmia).
Inhibition of Ca2+ influx
(eliminated Ca2+ handling
abnormalities and arrhythmia,
and restoration of normal
beating frequency)
Lan et al.
(2013) [121]
Arrhythmogenic
right ventricular
cardiomyopathy
EBs
↓PKP2 and plakoglobin. ↓Cx43.
↑Maximum width in CM.
Disorganised Z-bands. ↑Distorted
desmosomes#. Altered lipid droplet
morphology. ↑Lipid droplets and
accumulation. ↑PPAR-gamma and
-alpha. ↑Susceptibility to apoptosis.
↓Beta-catenin. Abnormal [Ca2+]
𝑖
handling capability. ↓Serca2a and
Na+/Ca2+ exchanger 1
Activation of canonical Wnt
signalling (↓lipid droplet
accumulation). Induction of
adult-like energy metabolism
and overactivation of
PPAR-gamma signalling
(increased apoptosis and lipid
accumulation). Lentiviral
transduction of WT PKP2
(redistribution of plakoglobin to
cell membrane and nucleus,
↓apoptosis, and lipogenesis).
Scavenging of reactive oxygen
species (↓apoptosis). Enrichment
for right ventricle-like CMs
(↑lipogenesis and apoptosis)
Ma et al.
(2013) [122],
Caspi et al.
(2013) [123],
and Kim et al.
(2013) [124]
Long QT
syndrome 1 EBs
Longer action potentials with
slower repolarisation velocities in
ventricular- and atrial-like CMs.
↓K+ currents. Translocation of
KCNQ1 from the cell surface to the
endoplasmic reticulum
Transduction of WT KCNQ1
(redistribution to the cell surface
of H9c2 cells). Beta-adrenergic
stimulation (impaired rate
adaptation of the AP and EADs),
rescued by nonselective
beta-blockade
Moretti et al.
(2010) [74]
Long QT
syndrome 2
iPSC coculture
with END-2 cells
[75]. EBs [125].
Directed
differentiation
method [126]
↑Field potential durations on
microelectrode arrays. Prolonged
cardiac repolarisation phase of the
AP (ventricular-like
CMs).↑Arrhythmogenicity.
Presence of EADs. Prolonged
[Ca2+]
𝑖
transients. ↓Densities of
rapid delayed potassium channels.
↑Sensitivity to the antiarrhythmic
drug, sotalol and the human
Ether-a`-go-go-related gene (hERG)
blocker E-4031. ↑Sensitivity to
beta-adrenoreceptor agonism
Nonspecific beta-adrenergic
agonist (↑chronotropy).
Pharmacological QT
prolongation (arrhythmogenic
behaviour). K+ channel
enhancement (shortened APs
and prevention of EADs). Ca2+
channel blockade (shortened
APs)
Lahti et al.
(2012) [76],
Matsa et al.
(2011) [126],
and Spencer
et al. (2014)
[127]
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Table 2: Continued.
NICM Cultureenvironment CM disease readouts
∗ Selected interventions (effect)∗ Reference
Long QT
syndrome 3
(Brugada
syndrome)
iPSC coculture
with END-2 cells
↓Inward Na+ current density.
Defective biophysical properties of
Na+ channel. Prolonged
inactivation of Nav1.5. Mild
prolongation of after-depolarising
potential. Altered SR Ca2+ release.
DADs and arrhythmias
None
Davis et al.
(2012) [128]
and Fatima et
al. (2013)
[129]
Timothy syndrome EBs
Slower (30 bpm) and more irregular
contraction rates.
↓Voltage-dependent inactivation of
the L-type Ca2+ channel current.
Longer APs (only in ventricular-like
CMs). Presence of DADs. Larger
and prolonged Ca2+ elevations
Pharmacological ↑ of
voltage-dependent inactivation
(↓irregular timing and amplitude
of Ca2+ transients, and AP
duration)
Yazawa et al.
(2011) [130]
Catecholaminergic
polymorphic
ventricular
tachycardia
iPSC coculture
with END-2 cells
↑Ca2+ amplitudes and longer
durations of spontaneous Ca2+
release events (persisted after
repolarisation). DADs and
arrhythmias
Catecholaminergic stimulation
(↑diastolic [Ca2+], ↓SR Ca2+
content, DADs, and
arrhythmias). ↑Cytosolic cAMP
levels (prevented Ca2+ induced
Ca2+ release events).
Pharmacological stabilisation of
the closed state of RyR channels
(normalised Ca2+ spark
properties)
Fatima et al.
(2011) [131]
and Jung et
al. (2012)
[132]
LEOPARD
syndrome EBs
↑Median CM surface area.
↑Sarcomere assembly. ↑NFATc4
nuclear translocation.
↑Phosphorylation of EGFR and
MEK1 (in iPSCs)
None
Carvajal-
Vergara et al.
(2010) [133]
Hypoplastic left
heart syndrome
Directed
differentiation
method
Less organised sarcomeres.
↓Cardiac progenitor marker Mesp1.
Retarded but persistent GATA4
expression. ↑MYH6 (fast isoform).
↓cTnT and Cx43 expression. ↑Atrial
natriuretic peptide. ↓Numbers and
beating rates of contractile areas.
Accelerated rate of Ca2+ transient
decay. RyR and SR dysfunction.
↑Inositol trisphosphate receptor
Beta-adrenergic receptor
agonism (lower increases in beat
frequency)
Jiang et al.
(2014) [134]
Duchenne
muscular
dystrophy
EBs [135]. Directed
differentiation
method [136, 137].
Staged: days 1–16
EBs + directed
differentiation,
days 20–24
maturation on
hydrogel substrate
with a
physiological
stiffness [138]
↓Dystrophin expression. Abnormal
Ca2+ handling. ↓Numbers of
spontaneously contracting
embryoid bodies and cTnT-positive
CMs. ↑Apoptotic markers: Ca2+
overload, mitochondrial damage,
caspase-3 activation, and cell death
Beta-adrenergic receptor
agonism (↑beating rates).
Antisense oligonucleotides exon
skipping (exon skipping and
dystrophin expression).
Minidystrophin gene construct
(restored dystrophin expression).
Human artificial chromosome
carrying the whole dystrophin
genomic locus (restored
dystrophin expression including
multiple isoforms and correct
subcellular localisation).
Oxidative stress (earlier
mitochondrial permeability pore
opening). Hypotonic stress
(↑susceptibility). Membrane
sealing (↓apoptotic markers)
Dick et al. (in
press) [136],
Guan et al.
(2014) [138],
Zatti et al.
(2014) [137],
and Lin et al.
(2015) [139]
∗Or in other cell types where specified.
#Desmosomal widening correlated with lipid droplet accumulation.
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Figure 1: Modelling cardiac diseases with iPSC-CMs. Numerous stakeholders are involved in modelling cardiac diseases using iPSC-CMs:
patients, patients’ family members, or anonymous biobank donors who provide the founder cells, for example, skin fibroblasts or PBMCs,
and also clinicians, biomedical researchers, and members of industry who participate in the collection of samples, the generation of iPSCs
followed by differentiation into iPSC-CMs, and modelling underlying cardiac pathology and using state-of-the-art approaches, for example,
bioengineered stimulating microdevice [25] and drug screening, to advance the impact of iPSC-CMs.
which may, at worst, be merely artificial features of a growth
environment with insufficient recapitulation of the disease
pathophysiology.
Genetic ion channelopathies such as long QT syndromes
(LQTS) have been adequately modelled by different groups:
LQT1 by Moretti et al. [74] and LQT2 by Lahti et al. [76],
Matsa et al. [126], and Spencer et al. [127]. These models
demonstrated several disease hallmarks in CMs derived from
symptomatic patients’ iPSCs, for example, prolonged AP
duration with lower peak amplitudes, abnormal colocalisa-
tion of potassium channel voltage gated KQT-like subfam-
ily Q member 1 (KCNQ1) to the endoplasmic reticulum
(ER), decreased and altered delayed rectifier K+ current S
(𝐼Ks) currents, early after depolarisations (EADs) upon adren-
ergic challenge, and ameliorating responses to antiarrhyth-
mic drugs. Additionally, Brugada syndrome or LQT3 has
also been modelled with patient specific iPSC-CMs by two
groups [128, 129] where again altered electrophysiological
profiles such as reduced upstroke velocity, decreased inward
Na+ channel (𝑙Na+) density, and longer action potential dura-
tion (ADP90) with quicker pace frequencies were evident.
Interestingly, the cardiac pathology of Timothy syndrome,
which is a more complicated LQTS as it involves defects
in both K+/Na+ channels, was demonstrated by Yazawa et
al. [130]. Disease-specific electrical defects were shown in
Timothy syndrome patients’ iPSC-CMs such as low beating
rate (bradycardia) and lower inactivation of L-type Ca2+
channels which were reversed by roscovitine, a cyclin-
dependent kinase inhibitor that increases voltage-dependent
inactivation. Lastly, catecholaminergic polymorphic ven-
tricular tachycardia (CPVT), a stress-induced ventricular
rhythm disease caused bymutations in the cardiac ryanodine
receptor isoform 2 (RyR2) gene, has also been shown in
CMs derived from iPSCs isolated from patients with CPVT
(CPVT1-CMs) [131, 132]. CPVT1-CMs developed arrhyth-
mias, delayed after depolarisations, abnormal Ca2+ handling,
and negative chronotropic responses following isoproterenol
treatment.
Carvajal-Vergara et al. [133] have generated CMs from
patients with LEOPARD syndrome (LS) which causes hyper-
trophic cardiomyopathy due to mutations in the protein
tyrosine phosphatase nonreceptor type 11 (PTPN11) gene
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encoding the protein tyrosine phosphatase containing a Src
homology 2 domain (SHP2) phosphatase protein which is
involved in rat sarcoma mitogen-activated protein kinase
(RAS-MAPK) signalling. LS-CMs had increased median
surface area and sarcomere assembly with a dephosphory-
lated calcineurin-dependent delocalisation of nuclear factor
of activated T-cells, cytoplasmic calcineurin-dependent 4
(NFATc4) to the nuclei, and abnormal RAS-MAK signalling
(epidermal growth factor receptor (EGFR) and mitogen-
activated protein kinase kinase (MEK1) phosphorylation).
Captivatingly, the alterations in RAS-MAK signalling were
observed in iPSCs not iPSC-CMs indicating that the disease
pathological mechanisms become altered as early as the cells
of the inner cell mass in the developing embryo (the natural
equivalents of iPSCs). Furthermore, iPSC-CMs from patients
with hypoplastic left heart syndrome (HLHS) have been used
to model the disease mechanisms of HLHS [134] which
to date remain unclear. Cardiovascular malformations and
cardiomyopathy are present in the earlyHLHS foetus. HLHS-
CMs displayed downregulated mesoderm posterior basic
helix-loop-helix transcription factor 1 (MESP1) and cTnT and
randomly arranged myofibrils, RyR2 dysfunction, and lower
beating rates. Coupled to these differences, changes inHLHS-
iPSCs were also noted, specifically in cardiogenic capability
of diseased iPSCs, indicating that both developmental and
functional failings in iPSCs and CMs, respectively, may be
responsible for impaired cardiogenesis in HLHS.
Dystrophinopathies are a group of X-linked genetic
muscle diseases that are caused by mutations in the dys-
trophin gene which encodes the dystrophin protein. Mus-
cular dystrophy (MD) patients have varying disease pheno-
types dependent upon the severity of the mutation [141].
Although skeletal muscle is the main tissue affected in
dystrophinopathies, MD patients are increasingly dying from
cardiac disease typified by cardiomyopathy complicated by
arrhythmias [135]. In late 2013 and early 2014 a trio of
papers [136–138] presented the derivation of iPSC-CMs from
Duchenne MD patients (DMD-CMs) and the successful
demonstration of CM-specific pathology associated with this
early onset severe form of MD. In 2015 an additional report
of DMD-CMs followed on from the initial studies, this time
also focusing on the Duchenne type of MD [139]. Interest-
ingly, certain groups investigating Duchenne MD aimed to
restore dystrophin expression through various approaches:
exon-skipping antisense oligonucleotides [142], dystrophin
minigenes [136], human artificial chromosome containing
dystrophin sequences [137], and genome editing with TAL-
ENs orCRISPR-Cas9 [143].Notably, the Elvassore group [137]
used a growth substrate with a relevant physiological stiffness
(15 kPascal) which improved the maturity of DMD-CMs
which displayed mature sarcomeric organisation and shorter
calcium transients (<1 s).The reports by Guan et al. [138] and
Lin et al. [139] focused on the molecular mechanisms of MD
cardiac disease. Specifically these groups found that the lack
of dystrophin in DMD-CMs resulted in elevated Ca2+ levels
and abnormal Ca2+ handling, mitochondrial permeability
pore opening, increased susceptibility to hypotonic stress
and elevated cardiac injury markers (creatine kinase-MB and
cardiac troponin I) [138], and increased apoptosis [139]. Some
of these molecular mechanisms were reversed in response
to treatment of DMD-CMs with different potential MD
therapeutics such as the membrane sealant Poloxamer 188
[139]. Additionally, Guan et al. [138] provided evidence that
MD heart failure develops largely through independent
mechanisms not linked to respiratory failure which repre-
sents a groundbreaking advance in the understanding of MD
cardiac disease.
Undoubtedly, iPSC-CMs are a promising tool for cardiac
disease modelling despite their functional immaturity. How-
ever, avoiding artifice is essential when interpreting results
generated from iPSC-CMs. Thus, focusing on a palpable
defect present and identifiable in patients’ CMs which corre-
sponds to a clinically meaningful component of the under-
lying disease and redressing the lack of pathophysiological
cues in the cell-culture environment are the leading avenues
of research which should generate more powerful disease
models.
6. Value to the Clinic and Future Perspectives
Several national and international efforts to build iPSC
biobanks point towards an optimistic future for the clinical
application of iPSC-CMs, even in situations where the need
is acute, for example, myocardial infarction. Biobanks aim
to accumulate stocks of iPSCs which have been prepared
under GMP conditions and have a fully traceable derivation
and characterisation record. Furthermore, iPSCbiobankswill
curate samples from individuals with genetic disorders and
produce other iPSC lines from healthy individuals for use
in HLA-haplotype-matched allografts. These steps will help
the clinical translation of basic research on cells derived
from iPSCs and the development of iPSC lines for use
in drug toxicology screening. Unfortunately, the lack of
standard operating procedures for the culture of iPSCs, cell
heterogeneity in iPSC cultures and progeny cells, genomic
instability, and potential tumourigenicity implies that sig-
nificant hurdles remain [144] and further basic research is
needed in parallel to meticulously planned safety-focused
clinical trials. Intriguingly there is an apparent shift towards
the use of allogeneic rather than autologous iPSCs as evident
by the suspension of the world’s first clinical trial of iPSCs
(for age-related macular degeneration), other clinical trials
altering trial protocols to utilise allogeneic over autologous
iPSCs and perhapsmost tellingly the advent of iPSC biobanks
stocking HLA-haplotype diverse iPSCs. Notably it has been
estimated that an iPSC biobank containing between 50
and 200 lines of HLA-haplotype characterised iPSCs would
adequately provide matched cells for millions of individuals
[56, 57].Thus, allograft cells could bemore advantageous over
allogeneic cells.
Cardiovascular trials of iPSC-based therapies are likely
imminent and it will be interesting to learn the details
regarding the source of iPSCs (autologous or allogeneic),
maturity stage of the transplanted cells, and whether any
bioengineering approaches were used in the cell product, for
example, growth of cells on scaffolds. Overall, this is a period
of immense opportunity to refine protocols and discover the
latent potential of iPSCs in the cardiology clinical setting.
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